Atlas Trials

Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy

Clinical trial NCT00469729 · COMPLETED

Trial details

NCT number
NCT00469729
Sponsor
Gamida Cell -Teva Joint Venture Ltd.
Status
COMPLETED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Hematologic MalignanciesAcute Myeloid LeukemiaLymphoid LeukemiaChronic Myeloid LeukemiaHodgkin's DiseaseNon-Hodgkin's LymphomaMyelodysplastic Syndromes
Start date
2007-10-01
Primary completion
2013-02-01
Enrollment
101

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.